Physician profile
Matt Mors
NPI 1871904698
$761.25
in general payments reported to CMS, 2019-2025
25 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $53.38 · 2021: $19.21 · 2022: $66.75 · 2023: $50.33 · 2024: $86.29 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $298.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $126.62 | 2019-2024 | |
| Medtronic USA, INC. | $106.38 | 2019 | |
| Novo Nordisk INC | $63.66 | 2019-2025 | Wegovy |
| Exact Sciences Corporation | $42.50 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $35.80 | 2019 | |
| Dexcom, INC. | $33.66 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $25.26 | 2025 | Recorlev |
| Dynavax Technologies Corporation | $23.50 | 2024 | Heplisav-B |
| Teva Pharmaceuticals USA, INC. | $23.24 | 2025 | Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $22.54 | 2022 | |
| Pfizer INC. | $22.44 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $22.24 | 2019 | |
| Viatris Specialty LLC | $21.34 | 2025 | Yupelri |
| Corcept Therapeutics | $21.23 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.77 | 2024 | Synjardy, Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $19.21 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.57 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.67 | 2023 | Farxiga |
| Biohaven Pharmaceuticals, INC. | $16.11 | 2020 | |
| Sonex Health, INC. | $15.22 | 2025 | Sx-One Microknife |
| Lilly USA, LLC | $15.00 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $13.87 | 2022 | |
| Allergan, INC. | $12.84 | 2020 | |
| Glaxosmithkline, LLC. | $12.77 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matt Mors listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.